Levothyroxine in euthyroid autoimmune thyroiditis and type 1 diabetes: a randomized, controlled trial.

Area of Science:

• Endocrinology
• Pediatric Endocrinology
• Immunology

Background:

• Type 1 diabetes (T1D) patients exhibit an elevated risk for developing autoimmune thyroiditis (AIT).
• Identifying early markers and preventive strategies for AIT in T1D is crucial.

Purpose of the Study:

• To investigate if levothyroxine (l-T(4)) treatment can prevent the clinical onset of AIT in euthyroid individuals with T1D.
• To assess the impact of l-T(4) on thyroid volume, function, and autoantibody levels in this population.

Main Methods:

• A prospective, randomized, open-label clinical trial was conducted across six pediatric endocrinology centers.
• Thirty euthyroid children and adolescents with T1D and positive thyroid antibodies were randomized to receive l-T(4) or no treatment for 24 months.
• Thyroid ultrasound, TSH, thyroid hormones, TPOAb, and TgAb levels were monitored every six months for 30 months.

Main Results:

• Levothyroxine treatment led to a significant decrease in mean thyroid volume compared to the observation group.
• No significant differences were observed between groups in serum thyrotropin, free T(4), TPOAb, or TgAb levels.
• The incidence of hypothyroidism was similar in both the l-T(4) treatment and untreated groups.

Conclusions:

• Levothyroxine treatment in euthyroid patients with T1D and AIT effectively reduced thyroid gland volume.
• l-T(4) administration did not demonstrate a significant effect on preventing thyroid dysfunction or altering serum autoantibody levels.
• Further research may be needed to explore long-term outcomes and alternative interventions for AIT in T1D.